Harmony Biosciences Holdings, Inc. (HRMY) stock
HRMYNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 18/3039% below fair value
$33.11+0.10 (+0.30%)
Close on Nov 18, 2026Market cap $1.93BP/E 10.7Yield –
Harmony Biosciences operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Harmony Biosciences's operating cash flow for the twelve months ending Jun 30, 2026 was $355.08M, up 36.9% year over year. For fiscal 2025 it was $348.20M, up 58.4% from the year before. The highest annual figure on record is $348.20M in fiscal 2025.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $348.20M | +58.4% |
| FY2024 | Dec 31, 2024 | $219.82M | +0.2% |
| FY2023 | Dec 31, 2023 | $219.39M | +51.9% |
| FY2022 | Dec 31, 2022 | $144.47M | +46.6% |
| FY2021 | Dec 31, 2021 | $98.56M | – |
| FY2020 | Dec 31, 2020 | -$2.99M | – |
| FY2019 | Dec 31, 2019 | -$75.44M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $92.43M | +16.5% |
| Q1 FY2026 | Mar 31, 2026 | $27.76M | -18.3% |
| Q4 FY2025 | Dec 31, 2025 | $126.15M | +67.0% |
| Q3 FY2025 | Sep 30, 2025 | $108.73M | +54.2% |
| Q2 FY2025 | Jun 30, 2025 | $79.33M | +86.1% |
| Q1 FY2025 | Mar 31, 2025 | $33.99M | +9.1% |
| Q4 FY2024 | Dec 31, 2024 | $75.56M | -1.4% |
| Q3 FY2024 | Sep 30, 2024 | $70.50M | +11.7% |
| Q2 FY2024 | Jun 30, 2024 | $42.62M | +15.0% |
| Q1 FY2024 | Mar 31, 2024 | $31.14M | -26.8% |
| Q4 FY2023 | Dec 31, 2023 | $76.67M | +187.4% |
| Q3 FY2023 | Sep 30, 2023 | $63.10M | +14.3% |
| Q2 FY2023 | Jun 30, 2023 | $37.06M | +9.9% |
| Q1 FY2023 | Mar 31, 2023 | $42.56M | +47.5% |
| Q4 FY2022 | Dec 31, 2022 | $26.68M | -28.9% |
| Q3 FY2022 | Sep 30, 2022 | $55.21M | +81.5% |
| Q2 FY2022 | Jun 30, 2022 | $33.73M | +86.7% |
| Q1 FY2022 | Mar 31, 2022 | $28.85M | +130.3% |
| Q4 FY2021 | Dec 31, 2021 | $37.53M | +273.6% |
| Q3 FY2021 | Sep 30, 2021 | $30.42M | +244.2% |
| Q2 FY2021 | Jun 30, 2021 | $18.07M | +274.0% |
| Q1 FY2021 | Mar 31, 2021 | $12.53M | – |
| Q4 FY2020 | Dec 31, 2020 | $10.05M | – |
| Q3 FY2020 | Sep 30, 2020 | $8.84M | – |
| Q2 FY2020 | Jun 30, 2020 | $4.83M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$23.99M | – |
See a number that looks wrong?